AI Terminal

MODULE: AI_ANALYST
Interactive Q&A, Risk Assessment, Summarization
MODULE: DATA_EXTRACT
Excel Export, XBRL Parsing, Table Digitization
MODULE: PEER_COMP
Sector Benchmarking, Sentiment Analysis
SYSTEM ACCESS LOCKED
Authenticate / Register Log In

Vetoquinol SA

Report Publication Announcement Dec 15, 2014

1747_iss_2014-12-15_efd55c6f-834e-4670-9947-2d423034fd78.pdf

Report Publication Announcement

Open in Viewer

Opens in native device viewer

2015 CALENDAR OF FINANCIAL COMMUNICATION

December 15, 2014 (Lure, France) – Vétoquinol published its calendar of financial communication for 2015.

January 22, 2015 2014 Annual revenues (after market)
March 23, 2015 2014 Annual results (after market)
Investor's presentation on March 24
April 14, 2015 2015 First quarter revenues (after market)
May 20, 2015 Annual shareholders' meeting
June 4, 2015 Dividend distribution
July 30, 2015 2015 Interim revenues and interim results (after market)
October 22, 2015 2015 Third quarter revenues (after market)
January 21, 2016 2015 Annual revenues (after market)

Next update: 2014 Annual revenues, January 22, 2015 after market close

About Vétoquinol

Vétoquinol is a leading global player in the animal health sector serving both the livestock (cattle and pigs) and pet (dogs and cats) markets.

An independent pure player, Vétoquinol designs, develops and sells veterinary drugs and non-medicinal products in Europe, the Americas and the Asia Pacific region.

Since its foundation in 1933, Vétoquinol has pursued a strategy combining innovation with geographical diversification. The Group's hybrid growth is driven by the reinforcement of its product portfolio coupled with acquisitions in high potential growth markets. Vétoquinol employs 1,977 people. Vétoquinol has been listed on NYSE Euronext Paris since 2006 (symbol: VETO).

For more information: www.vetoquinol.com.

OUR BUSINESS: ANIMALS. OUR ADVANTAGE: PEOPLE.

For more information, contact:

VETOQUINOL KEIMA COMMUNICATION Investor Relations Marie-Josée AUBRY-ROTA Tel.: +33 (0)3 84 62 59 88 [email protected]

Investor Relations and Media Relations Emmanuel DOVERGNE Tel.: +33 (0)1 56 43 44 63 [email protected]

Talk to a Data Expert

Have a question? We'll get back to you promptly.